Fuprine-100

Description

Fuprine-100 is listed as a flupirtine maleate 100 mg formulation in the supplied product information. Flupirtine is a centrally acting, non-opioid analgesic that has historically been used for pain management. However, serious liver injury concerns have led to major restrictions and withdrawal of flupirtine-containing medicines in several markets.

Before listing Fuprine-100 for sale or promotion, confirm its current regulatory approval, permitted indications and marketing status in India. The product should not be promoted or used unless its sale and use are legally authorised.

Therapeutic Segment

Pain Management | Centrally Acting Analgesic

Catalog note: The supplied category is “Anti-inflammatory.” Flupirtine is primarily classified as an analgesic rather than a conventional anti-inflammatory medicine. Consider updating the category if your approved catalog structure allows it.

Uses of Fuprine-100

Flupirtine has historically been used for pain relief. However, due to its association with serious liver injury and regulatory restrictions, no current indication should be promoted for Fuprine-100 without confirming the approved Indian product information.

Do not present this product as a routine option for inflammatory conditions or recommend it for self-medication.

Key Product Information

• Active Ingredient: Flupirtine maleate
• Strength: 100 mg
• Historical Pharmacological Class: Centrally acting, non-opioid analgesic
• Packaging: Blister
• Pack Size: 10 × 10 units

How Flupirtine Works

Flupirtine has been described as acting on neuronal potassium channels, helping regulate neuronal excitability and pain signalling. Its pharmacological action differs from that of conventional non-steroidal anti-inflammatory drugs (NSAIDs).

This mechanism does not establish that the product is currently approved, appropriate or safe for routine use.

Important Safety Information

Flupirtine has been associated with serious liver injury, including cases of acute liver failure. Regulatory authorities in several markets have taken action against flupirtine-containing medicines because of this risk.

• Verify the product’s current Indian regulatory status before marketing, prescribing or dispensing it.
• Do not use this product without confirmation that it is legally authorised and appropriate for the intended patient.
• Do not publish unverified indications, dosage instructions or safety claims.
• If a patient has already taken flupirtine and develops symptoms such as yellowing of the skin or eyes, dark urine, persistent nausea, unusual fatigue or abdominal pain, they should seek urgent medical assessment.
• Consult the applicable approved product information and qualified healthcare professionals for safety decisions.

Dosage and Administration

No dosage recommendation is provided here because the current approval status and applicable product information must first be verified. Do not infer a dosing schedule solely from the stated strength of 100 mg.

Storage Instructions

Follow the storage conditions printed on the approved product label. Confirm the authorised pack artwork and product documentation before publishing storage details.